mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer

Table 2

Clinical trials of mTOR inhibitors in head and neck cancer.

Drugs	Treatment regimens	Study phase and disease status	Identifier no.
Rapamycin	Rapamycin once daily for 21 days followed by surgery	Phases I/II study in advanced head and neck cancer	NCT01195922
Temsirolimus	Temsirolimus with or without cetuximab	Phase II study in recurrent and/or metastatic head and neck cancer	NCT01256385
Temsirolimus	Temsirolimus	Phase II study in relapsed/recurrent; head and neck cancer	NCT01172769
Temsirolimus	Temsirolimus, paclitaxel, and carboplatin	Phases I/II study in recurrent or metastatic head and neck cancer	NCT01016769
Temsirolimus	Temsirolimus, cisplatin, and cetuximab	Phases I/II study in recurrent or metastatic head and neck cancer	NCT01015664
Everolimus	Everolimus, docetaxel, and cisplatin	Phase I study in local-regional advanced head and neck cancer	NCT00935961
Everolimus	Carboplatin, cetuximab, and everolimus	Phases I/IIB study in recurrent metastatic head and neck cancer	NCT01283334
Everolimus	Everolimus, carboplatin, and paclitaxel	Phases I/II study in locally advanced head and neck cancer	NCT01333085
Everolimus	Everolimus, cetuximab	Phase I study in recurrent or metastatic head and neck cancer	NCT01637194
Everolimus	Everolimus	Phase II study in refractory, recurrent, and locally advanced head and neck cancer	NCT01051791
Everolimus	Everolimus, erlotinib	Phase II study in recurrent head and neck cancer	NCT00942734
Everolimus	Everolimus, placebo	Phase II study in locally advanced head and neck cancer	NCT01133678